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Summary
Primary hyperparathyroidism (HPT) is observed in 20-30% of
patients with multiple endocrine neoplasia type 2A (MEN 2A).
The age of diagnosis ranges from seven to seventy one year
old (with median of thirty eight years) in patients affected by
HPT in MEN 2A. We diagnosed primary HPT in a 5 year old
boy carrier of RET gene mutation associated with MEN 2A,
submitted to prophylactic total thyroidectomy (TT).
The RET mutated gene carriers are submitted to prophylactic
TT at different ages. Recent studies demonstrated that based
on the type of RET gene mutation the timing of TT varies, as
the transforming potential of RET-mutations are codon-depen-
dent with significant correlations between genotype and clini-
cal phenotype in MEN 2A patients. In particular, the medullary
thyroid carcinoma (MTC) occurs earlier in the patients with
codon 634 mutations than in those with other mutations, and
these patients have also a higher frequency of pheochromo-
cytoma and hyperparathyroidism.
This genotype-phenotype correlation is confirmed in the pa-
tient described in this report, who was carrier of a germline
mutation in the 634 codon (Cys→Trp) and showed early ex-
pression of MTC and parathyroid pathology. The young age of
this patient represents an exception, as other Authors report
the absence of parathyroid pathology in children or in adoles-
cents submitted to prophylactic TT.
The patient underwent a partial parathyroidectomy in agree-
ment with the preferred surgical treatment of HPT in MEN 2A,
which consists in removing only the parathyroid(s) with in-
creased volume. Indeed, the experiences with subtotal or total
parathyroidectomy associated to autograft are very limited,
with results supporting lack of major differences and, there-
fore, suggesting a more conservative surgical approach.
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Introduction
Primary hyperparathyroidism (HPT) is observed in 20-30% of
patients with multiple endocrine neoplasia type 2A (MEN 2A)
(1). The age of diagnosis in patients affected by HPT ranges
from seven to seventy one year old (with median of 38 years)
(2-4). The diagnosis of HPT is often made at the moment of
the total thyroidectomy (TT) performed for the cure or the pre-
vention of medullary thyroid carcinoma (MTC).
We diagnosed primary HPT in a 5 year old child affected by
MEN 2A, who has been submitted to prophylactic TT.
Case report
A 5-year-old child of male sex was admitted to our observation
in November 2002, since genetically diagnosed as MEN 2A
carrier. The mother was affected by pheocromocitoma,
medullar thyroid carcinoma and carrier of an activating muta-
tion of the RET gene. The child had a silent clinic picture and
underwent genetic analysis. The exam showed that he was
carrying the same (TGC→TGG) mutation of the RET gene on
the 634 codon of exon 11, with consequent aminoacidic substi-
tution Cys→Trp in the encoded protein.
Ultrasound exam of the superior abdomen and of the neck
(April 2003) did not identify significant alterations, with the ab-
sence of lesions at bilateral suprarenal level and regular thy-
roid as regard size and structure.
Biochemical exams showed abnormal levels (20.3 pg/ml; n.v.:
male • 15.9 pg/ml, female • 8.5 pg/ml) of circulating calcitonin.
Also non specific enolase (NSE) was higher than normal (16.7
ng/ml; n.v.: 0.0-13.0 ng/ml), urinary excretion of the principal
adrenergic hormones (vanylmandelic acid, metanephrine and
normetanephrine) was within the normal range (1.82 mg/24h,
55 mcg/24h, 135 mcg/24h respectively; n.v.: 1.80-6.70 mg/24h,
52-341 µg/24h, 88-440 µg/24h), as also chromogranin A (CgA)
(62 ng/ml; n.v.: • 123 ng/ml). Surprisingly, serum concentra-
tions of ionized calcium and PTH were respectively 4.72 mg/dl
(n.v.:4.10-5.30 mg/dl) and 44.4 pg/ml (n.v.:10-68 pg/ml). 
On July 2003 the child was admitted to our Surgery Unit and
underwent various diagnostic exams including pentagastrin
test that resulted positive showing an abnormal response of
calcitonin with a peak of 166 pg/ml after one min.
Both the genetic test and the biochemical profile of the patient
were indicative for surgery. For this reason on July 2003 the
child underwent total thyroidectomy with lymphadenectomy of
the central compartment and transcervical thymectomy. During
surgery all the parathyroid glands were identified. The superior
right and inferior left parathyroid were found enlarged
(7x3.5x3.8 mm, 6x4x3 mm, respectively) and, therefore, both
parathyroids were excised. The intraoperative histological ex-
am showed hyperplastic tissue at the superior right parathyroid
level (Fig. 1).
The postoperative histopathological diagnosis was of multifocal
medullary thyroid carcinoma with a major nodule measuring 3
mm in diameter, of hyperplastic lymphadenitis in the perithyroid
lymphonodes and of hyperplasia of the parathyroid glands
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(Figs. 1, 2 and 3A,B). The child was discharged with thyroid
substitutive therapy and a well controlled calcemia. At 17
months after surgery, he is in good health with normal calcium
and PTH levels and a negative pentagastrin test. 
Discussion
The RET mutated gene carriers are submitted to prophylactic
TT at different ages. Some Authors recommend TT at 5 years
of age in mutated gene carriers (5-7). Other Authors suggest
that TT at the age of 2 years (8-9) or between 3 and 5 years
(10) is necessary to obtain optimal cure rates. Recent studies
demonstrated that based on the type of RET gene mutation the
timing of TT varies, as the transforming potential of RET-muta-
tions is codon-dependent (11), with a significant correlation be-
tween genotype and clinical phenotype in MEN 2A patients
(12-15). In particular the risk to develop MTC and metastatic
MTC (MMTC) is genotype-dependent, with higher age-inde-
pendent risk of MTC and MMTC in c634 mutation carriers
(81%) than in c618 (34%) and c620 (7%) mutation carriers
(16). “In vitro” transfection studies confirmed these findings
with variable codon specific neoplastic transforming capacity of
c609, c611, c618, c620, c630, and c634 mutations in C-cells
and with the highest values for the c634 mutation (11). These
results were confirmed by the clinical observation that MTC oc-
curs earlier in patients with c634 mutation, whereas patients
with c611 and c804 mutations display a late expression of
MTC (12, 17-19). Moreover, in a recent review it has been re-
ported that the youngest patient with MTC, a one year old, car-
ried out the c634 RET mutation, while mutations in codons
c618, c804, and c620 have as earliest age of expression re-
spectively 7, 15, and 15 years (16). Therefore, the codon
analysis has prognostic value and the knowledge of specific
malignant potential of each codon may make possible to select
the timing of TT based on genotype (16). 
Interestingly, patients with codon 634 mutations have a higher
frequency of pheochromocytoma and hyperparathyroidism
than those with other mutations (14,15). These phenotypic
characteristics are confirmed in the patient described in this re-
port, who showed early expression of MTC and parathyroid
pathology and who is carrier of a germline mutation in the 634
codon (Cys→Trp).
Epidemiological data on the incidence of HPT in MEN 2A pa-
tients showed that HPT is observed more frequently in some
Figure 1 - Primary chief cell hyperplasia, with predominantly diffuse pat-
tern of growth.
Figure 2 - Low-power view of medullary carcinoma showing nests of
cells and deposition of amyloid.
Figure 3 - Medullary carcinoma showing strong positive immunostaining for calcitonin (A) and CEA (B).
A B
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families, whereas in others it is not present also after a long fol-
low-up from TT (20). These results have been explained on the
basis of a decreased risk of HPT due either by the excision or
by the damage of the parathyroids or by the possible elimina-
tion of a parathyroid stimulating factor produced by the C cells
(20, 21). On the basis of these observations and of the low risk
of onset of HPT in MEN2A, at present, the operation of prophy-
lactic parathyroidectomy does not seem indicated when
surgery for MTC is performed.
The young age of the patient described in this report repre-
sents an exception, as other Authors report the absence of
parathyroid pathology in patients submitted to prophylactic TT
in children’s or in adolescents (22, 23). The clinical and bio-
chemical features of our patient was entirely silent, in agree-
ment with the described lack of symptoms in MEN 2A hyper-
parathyroid patients (3, 4, 24). Furthermore, MEN 2A patients
can exhibit normal calcium and PTH serum values even if en-
larged parathyroid gland(s) were found at surgery and histolog-
ically confirmed at pathology (4).
In the natural history of HPT in MEN 2A patients, in the majority
(75-80%) of subjects the diagnosis of HPT is synchronous with
that of MTC or pheochromocitoma, in the remaining cases HPT
arises after many years from TT (1). HPT precedes the diagno-
sis of MTC or pheochromocitoma in less than 5% of the cases
(4). As in our patient the two enlarged parathyroids were both
hyperplastic, this case can be included in the 48% of cases with
diffuse hyperplasia of the parathyroids (3, 25). Conversely, the
presence of only one pathologic parathyroid gland (usually re-
ferred as single adenoma) at the surgical exploration is reported
in a variable percentage from 27 to 48% of MEN 2A cases (2, 4,
25, 26) and the double adenoma in about 8% (3, 25).
Concerning the surgical treatment the experience reported in
literature is scarce. The preferred surgical treatment is to limit
the removal to the enlarged parathyroid glands. The results of
the partial parathyroidectomy showed relapses of HPT in
20.9% of the cases, (mean variable follow-up from 3.5 to 11.4
years) (Table I). However, given that in a large part of the cas-
es (about 3/4) the treatment of HPT occurs during surgery for
MTC, it is not clear how many glands are effectively removed.
In fact, the TT and the frequent heed for lymphoadenectomy of
the central section of the neck (including often the thymecto-
my) can cause the extirpation or the devascularization of some
or all residual parathyroid glands. This is also confirmed by the
fact that in these experiences a high number of permanent hy-
poparathyroidism (10-19%) is present (Table I). Therefore, the
apparently favourable results of a partial parathyroidectomy
limited to the resection of the increased in volume glands
should be better evaluated and analyzed by prospective clini-
cal studies. Finally, the experience with subtotal or total
parathyroidectomy associated to autograft is very limited, even
though the accumulated data do not show major differences,
suggesting a more conservative surgical approach (Table I).
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